- Trial phase
- Phase 2
- Time to market
- Certepetide is in Phase 2 clinical development with no registered Phase 3 trial underway. Given the company's strategic pivot to cardioendocrine diseases, the timeline to potential approval is highly uncertain and likely several years away, if pursued at all.
- Why 3/10
- No upcoming binary catalyst (PDUFA date, pivotal readout, or regulatory decision) is scheduled for certepetide in the next ~12 months. The drug is now a legacy asset after Lisata's September 2026 acquisition of Marea Therapeutics pivoted the company to cardioendocrine diseases. ImpactScore is 3 because certepetide is an approved-stage-adjacent program with no imminent binary event at a company that has refocused elsewhere.
Certepetide is now a legacy pipeline asset for Lisata, which has pivoted to cardioendocrine diseases via the Marea acquisition. No upcoming binary catalyst (PDUFA, pivotal readout) is scheduled for certepetide. The final ASCEND Phase 2b data, expected Q1 2026, may have been released without fanfare given the corporate transformation. Watch for any out-licensing or partnership deal for certepetide, or its deprioritization in future pipeline updates.
Price Chart
Executive Summary
Certepetide (formerly LSTA1/CEND-1) is an investigational iRGD cyclic peptide designed to enhance tumor penetration of co-administered anti-cancer drugs. It showed encouraging Phase 2b ASCEND trial data in metastatic pancreatic cancer, with improved overall survival and complete responses versus placebo. However, after a tumultuous 2026 that included a failed Kuva Labs merger and a subsequent reverse merger with Marea Therapeutics, Lisata has pivoted from oncology to cardioendocrine diseases. Certepetide is now a legacy asset; the company's lead programs are MAR001 (Phase 2b for severe hypertriglyceridemia) and MAR002 (Phase 2 for acromegaly). No Phase 3 trial for certepetide has been initiated, and no upcoming binary catalyst is scheduled. The stock trades near its 52-week low with a reverse split incoming.
How It Works
Certepetide is a synthetic cyclic peptide (a small protein-like molecule) that exploits a natural transport system found only in solid tumors. When injected into the bloodstream, it activates a pathway that allows co-administered chemotherapy or other anti-cancer drugs to more deeply penetrate and accumulate inside tumors, rather than just reaching the tumor surface. It also changes the tumor's surrounding environment (microenvironment) to make it more vulnerable to immune-based therapies.
Trial Status
The Phase 2b ASCEND trial (Cohorts A and B) in metastatic pancreatic cancer reported positive preliminary data in 2025. Final data from both cohorts was anticipated for Q1 2026. A separate Phase 2 trial in advanced solid tumors (cholangiocarcinoma) has been completed. A Phase 1/2a CENDIFOX trial in resectable/borderline resectable pancreatic cancer is ongoing. Phase 3 preparations were discussed in 2025 but no Phase 3 trial has been initiated as of November 2026.
The Two-Sided Case
Upcoming Catalysts
- Potential out-licensing or partnership announcement for certepetide
- Possible publication of final ASCEND Phase 2b data
- Pipeline update from Lisata clarifying certepetide's strategic priority
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Lisata Therapeutics, Inc. Press Release LSTA ·Originating report